LigoCyte Pharmaceuticals

Contact Details: 920 Technology Blvd Bozeman MT 59718 United States of America Tel: 406585 2733 Fax: 406585 2766 Email: WWW: www.ligocyte.com/

Loading...

Recent Publications by LigoCyte Pharmaceuticals:
Influenza virus-like particle vaccines. Enveloped virus-like particle (VLP) vaccines containing influenza...	5th May, 2009	LigoCyte Pharmaceuticals, Inc., 2155 Analysis Drive, Bozeman, MT 59718,	Expert Rev Vaccines. 2009 Apr;8(4):435-45. DOI Direct Link
Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Influenza-pseudotyped Gag virus-like particles (VLPs) were produced via...	13th March, 2009	LigoCyte Pharmaceuticals, Inc. 2155 Analysis Dr., Bozeman, MT 59718, USA.	Vaccine. 2009 Jan 22;27(4):530-41. Epub 2008 Nov 19. DOI Direct Link
A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Here we confirm that intranasal (IN) dry powder anthrax vaccine...	16th January, 2009	LigoCyte Pharmaceuticals, Inc., 2155 Analysis Drive, Bozeman, MT 59718,	Vaccine. 2008 Oct 9;26(43):5494-502. Epub 2008 Aug 12. DOI Direct Link
An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. An intranasal vaccine targeting the Bacillus anthracis toxin and...	3rd October, 2006	LigoCyte Pharmaceuticals Inc., 2155 Analysis Drive, Bozeman, MT 59718,	Vaccine. 2006 May 1;24(18):3953-63. Epub 2006 Feb 28. DOI Direct Link

Press Releases on LigoCyte Pharmaceuticals:
Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment	26th October, 2009	Reportlinker	-- A focus on "engineered" antibodies Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge	8th September, 2009		BOZEMAN, Montana, September 8 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will

BioNews Results for LigoCyte Pharmaceuticals:
LigoCyte Pharma begins third human trial of its norovirus vaccine	PharmaBiz:  Sep 10 2009 6:08AM Matching: ligocyte pharmaceuticals
LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Incl	Pharma Live:  Sep 8 2009 12:40PM Matching: ligocyte pharmaceuticals
LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Incl	PR Newswire:  Sep 8 2009 10:15AM Matching: ligocyte pharmaceuticals

LigoCyte Pharmaceuticals Clinical Trials:
Phase 1 Norwalk Vaccine Study

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 864 times since April 2007, the link to the organisation's website has been followed 131 times

Recent Search Terms used to find this page: ligocyte.fr | ligocyte.fr | ligocyte | LigoCyte Pharmaceuticals Inc. email | ligocyte | ligocyte pharma email address | Ligocyte Influenza 2009 | ligocyte pharmaceuticals | virus like particle ligocyte | ligocyte | .

Search for more companies in Bozeman

Search for more companies in MT

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for LigoCyte Pharmaceuticals